Related Experiment Videos
Abstract:
Since January 1st 1975, 310 patients with traumatic hyphaema have been treated with the antifibrinolytic drug tranexamic acid. One secondary haemorrhage has occurred, corresponding to a frequency of secondary haemorrhage of 0.32%. Eighty-five of these patients were treated as out-patients. In four patients with traumatic hyphaema, who were not treated with tranexamic acid, the serum content of activator inhibitor was determined daily. An increase was seen during the first five days after the trauma, followed by a marked fall on the 6th day. In the same four patients, the central corneal thickness was followed by daily measurements and compared to the variation in activator inhibitor.
Insights
Tranexamic acid significantly reduces secondary hemorrhage risk in traumatic hyphaema patients, with only a 0.32% occurrence. This antifibrinolytic drug offers a safe and effective treatment option for eye trauma.
Area of Science:
- Ophthalmology
- Trauma Care
- Pharmacology
Background:
- Traumatic hyphaema can lead to secondary hemorrhage, a significant complication.
- Antifibrinolytic agents are used to manage bleeding disorders.
Purpose of the Study:
- To evaluate the efficacy of tranexamic acid in preventing secondary hemorrhage after traumatic hyphaema.
- To investigate the relationship between serum activator inhibitor levels and corneal thickness in untreated patients.
Main Methods:
- Retrospective analysis of 310 patients treated with tranexamic acid for traumatic hyphaema.
- Daily monitoring of serum activator inhibitor and central corneal thickness in four untreated patients.
Main Results:
- A low rate of secondary hemorrhage (0.32%) was observed in patients treated with tranexamic acid.
- Serum activator inhibitor levels increased in the first five days post-trauma and decreased by the sixth day in untreated patients.
Conclusions:
- Tranexamic acid is highly effective in preventing secondary hemorrhage in traumatic hyphaema.
- Further research is warranted to understand the role of activator inhibitor and corneal changes in hyphaema recovery.